Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.

MLA

Jones, David, et al. “Seladelpar (MBX-8025), a Selective PPAR-δ Agonist, in Patients with Primary Biliary Cholangitis with an Inadequate Response to Ursodeoxycholic Acid: A Double-Blind, Randomised, Placebo-Controlled, Phase 2, Proof-of-Concept Study.” The Lancet. Gastroenterology & Hepatology, vol. 2, no. 10, Oct. 2017, pp. 716–26. EBSCOhost, https://doi.org/10.1016/S2468-1253(17)30246-7.

APA

Jones, D., Boudes, P. F., Swain, M. G., Bowlus, C. L., Galambos, M. R., Bacon, B. R., Doerffel, Y., Gitlin, N., Gordon, S. C., Odin, J. A., Sheridan, D., Wörns, M.-A., Clark, V., Corless, L., Hartmann, H., Jonas, M. E., Kremer, A. E., Mells, G. F., Buggisch, P., … Hirschfield, G. M. (2017). Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. The Lancet. Gastroenterology & Hepatology, 2(10), 716–726. https://doi.org/10.1016/S2468-1253(17)30246-7

Chicago

Jones, David, Pol F Boudes, Mark G Swain, Christopher L Bowlus, Michael R Galambos, Bruce R Bacon, Yvonne Doerffel, et al. 2017. “Seladelpar (MBX-8025), a Selective PPAR-δ Agonist, in Patients with Primary Biliary Cholangitis with an Inadequate Response to Ursodeoxycholic Acid: A Double-Blind, Randomised, Placebo-Controlled, Phase 2, Proof-of-Concept Study.” The Lancet. Gastroenterology & Hepatology 2 (10): 716–26. doi:10.1016/S2468-1253(17)30246-7.